INNOGENELtd（A344860）株式概要株式会社イノジンは、アンチエイジングソリューションを提供しています。 詳細A344860 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金2/6リスク分析高いレベルの非現金収入 過去5年間で収益は年間42.7%減少しました。 過去1年間で株主の希薄化が進んだ 利益率(1.6%)は昨年より低い(8.7%) +1 さらなるリスクすべてのリスクチェックを見るA344860 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW463,021 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA463,021 investors already sharing narrativesYour Fair Value₩Current Price₩1.27k18.9% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-80m10b2016201920222025202620282031Revenue ₩9.0bEarnings ₩146.4mAdvancedSet Fair ValueView all narrativesINNOGENE Co.,Ltd. 競合他社Sewha P&CSymbol: KOSDAQ:A252500Market cap: ₩20.7bBIFIDOSymbol: KOSDAQ:A238200Market cap: ₩22.3bMedienceSymbol: KOSDAQ:A014100Market cap: ₩19.5bINSANSymbol: KOSDAQ:A277410Market cap: ₩21.4b価格と性能株価の高値、安値、推移の概要INNOGENELtd過去の株価現在の株価₩1,269.0052週高値₩2,800.0052週安値₩1,099.00ベータ-0.231ヶ月の変化-3.86%3ヶ月変化-16.18%1年変化-29.50%3年間の変化-67.12%5年間の変化-32.50%IPOからの変化40.38%最新ニュースNew Risk • Aug 20New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 43% per year over the past 5 years. High level of non-cash earnings (23% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (1.6% net profit margin). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (₩19.2b market cap, or US$13.8m).お知らせ • Aug 19INNOGENE Co.,Ltd. announced that it has received KRW 840 million in funding from Metamorphosis Co., Ltd. and another investorOn August 18, 2026, INNOGENE Co.,Ltd. closed the transaction. The shares are subject to one year lock-up.お知らせ • Jul 28INNOGENE Co.,Ltd. announced that it has received KRW 3.36 billion in funding from Metamorphosis Co., Ltd and Jeong Gi-chul.On July 27, 2026, INNOGENE Co.,Ltd. has closed the transaction.New Risk • Jun 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩15.2b (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 43% per year over the past 5 years. High level of non-cash earnings (23% accrual ratio). Market cap is less than US$10m (₩15.2b market cap, or US$9.74m). Minor Risk Profit margins are more than 30% lower than last year (1.6% net profit margin).New Risk • May 27New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 43% per year over the past 5 years. High level of non-cash earnings (23% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (1.6% net profit margin). Market cap is less than US$100m (₩18.0b market cap, or US$11.9m).Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₩1,334, the stock trades at a trailing P/E ratio of 69.9x. Average trailing P/E is 20x in the Personal Products industry in South Korea. Total loss to shareholders of 70% over the past three years.最新情報をもっと見るRecent updatesNew Risk • Aug 20New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 43% per year over the past 5 years. High level of non-cash earnings (23% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (1.6% net profit margin). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (₩19.2b market cap, or US$13.8m).お知らせ • Aug 19INNOGENE Co.,Ltd. announced that it has received KRW 840 million in funding from Metamorphosis Co., Ltd. and another investorOn August 18, 2026, INNOGENE Co.,Ltd. closed the transaction. The shares are subject to one year lock-up.お知らせ • Jul 28INNOGENE Co.,Ltd. announced that it has received KRW 3.36 billion in funding from Metamorphosis Co., Ltd and Jeong Gi-chul.On July 27, 2026, INNOGENE Co.,Ltd. has closed the transaction.New Risk • Jun 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩15.2b (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 43% per year over the past 5 years. High level of non-cash earnings (23% accrual ratio). Market cap is less than US$10m (₩15.2b market cap, or US$9.74m). Minor Risk Profit margins are more than 30% lower than last year (1.6% net profit margin).New Risk • May 27New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 43% per year over the past 5 years. High level of non-cash earnings (23% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (1.6% net profit margin). Market cap is less than US$100m (₩18.0b market cap, or US$11.9m).Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₩1,334, the stock trades at a trailing P/E ratio of 69.9x. Average trailing P/E is 20x in the Personal Products industry in South Korea. Total loss to shareholders of 70% over the past three years.お知らせ • Feb 06INNOGENE Co.,Ltd., Annual General Meeting, Mar 26, 2026INNOGENE Co.,Ltd., Annual General Meeting, Mar 26, 2026, at 10:00 Tokyo Standard Time. Location: conference room, guro-gu, seoul South KoreaUpcoming Dividend • Dec 22Upcoming dividend of ₩80.00 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 13 April 2026. Trailing yield: 3.8%. Within top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (1.8%).New Risk • Dec 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 36% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Profit margins are more than 30% lower than last year (2.9% net profit margin). Market cap is less than US$100m (₩27.1b market cap, or US$18.3m).お知らせ • Nov 12INNOGENE Co.,Ltd. announces Annual dividend, payable on April 13, 2026INNOGENE Co.,Ltd. announced Annual dividend of KRW 80.0000 per share payable on April 13, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.New Risk • Aug 28New major risk - Revenue and earnings growthEarnings have declined by 31% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (3.5% net profit margin). Market cap is less than US$100m (₩21.5b market cap, or US$15.5m).New Risk • May 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩31.1b market cap, or US$22.3m).New Risk • Jul 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (₩30.3b market cap, or US$22.0m).New Risk • Aug 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (₩48.2b market cap, or US$36.0m).お知らせ • Sep 07INNOGENE Co.,Ltd. has filed an IPO.INNOGENE Co.,Ltd. has filed an IPO. Security Name: Shares Security Type: Common Stock Price\Range: KRW 2500 to KRW 3000Is New 90 Day High Low • Feb 24New 90-day high: ₩1,200The company is up 19% from its price of ₩1,010 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 13% over the same period.お知らせ • Feb 10INNOGENE Co.,Ltd., Annual General Meeting, Mar 24, 2021INNOGENE Co.,Ltd., Annual General Meeting, Mar 24, 2021, at 10:00 Korea Standard Time.Is New 90 Day High Low • Jan 05New 90-day high: ₩1,175The company is up 7.0% from its price of ₩1,100 on 07 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 9.0% over the same period.株主還元A344860KR Personal ProductsKR 市場7D-9.0%-1.3%0.4%1Y-29.5%20.9%106.9%株主還元を見る業界別リターン: A344860過去 1 年間で20.9 % の収益を上げたKR Personal Products業界を下回りました。リターン対市場: A344860は、過去 1 年間で106.9 % のリターンを上げたKR市場を下回りました。価格変動Is A344860's price volatile compared to industry and market?A344860 volatilityA344860 Average Weekly Movement9.0%Personal Products Industry Average Movement9.3%Market Average Movement9.8%10% most volatile stocks in KR Market17.6%10% least volatile stocks in KR Market5.1%安定した株価: A344860 、 KR市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: A344860の 週次ボラティリティ ( 9% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2005n/aGwangHun Leewww.innogene.com株式会社イノジンはアンチエイジング・ソリューションを提供している。同社は2005年に設立され、韓国のソウルに本社を置いている。もっと見るINNOGENE Co.,Ltd. 基礎のまとめINNOGENELtd の収益と売上を時価総額と比較するとどうか。A344860 基礎統計学時価総額₩18.31b収益（TTM）₩146.39m売上高(TTM)₩9.04b125.1xPER（株価収益率2.0xP/SレシオA344860 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A344860 損益計算書（TTM）収益₩9.04b売上原価₩2.83b売上総利益₩6.21bその他の費用₩6.06b収益₩146.39m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）10.14グロス・マージン68.70%純利益率1.62%有利子負債／自己資本比率0%A344860 の長期的なパフォーマンスは？過去の実績と比較を見る配当金7.1%現在の配当利回りn/a配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/21 17:07終値2026/08/21 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋INNOGENE Co.,Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Aug 20New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 43% per year over the past 5 years. High level of non-cash earnings (23% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (1.6% net profit margin). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (₩19.2b market cap, or US$13.8m).
お知らせ • Aug 19INNOGENE Co.,Ltd. announced that it has received KRW 840 million in funding from Metamorphosis Co., Ltd. and another investorOn August 18, 2026, INNOGENE Co.,Ltd. closed the transaction. The shares are subject to one year lock-up.
お知らせ • Jul 28INNOGENE Co.,Ltd. announced that it has received KRW 3.36 billion in funding from Metamorphosis Co., Ltd and Jeong Gi-chul.On July 27, 2026, INNOGENE Co.,Ltd. has closed the transaction.
New Risk • Jun 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩15.2b (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 43% per year over the past 5 years. High level of non-cash earnings (23% accrual ratio). Market cap is less than US$10m (₩15.2b market cap, or US$9.74m). Minor Risk Profit margins are more than 30% lower than last year (1.6% net profit margin).
New Risk • May 27New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 43% per year over the past 5 years. High level of non-cash earnings (23% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (1.6% net profit margin). Market cap is less than US$100m (₩18.0b market cap, or US$11.9m).
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₩1,334, the stock trades at a trailing P/E ratio of 69.9x. Average trailing P/E is 20x in the Personal Products industry in South Korea. Total loss to shareholders of 70% over the past three years.
New Risk • Aug 20New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 43% per year over the past 5 years. High level of non-cash earnings (23% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (1.6% net profit margin). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (₩19.2b market cap, or US$13.8m).
お知らせ • Aug 19INNOGENE Co.,Ltd. announced that it has received KRW 840 million in funding from Metamorphosis Co., Ltd. and another investorOn August 18, 2026, INNOGENE Co.,Ltd. closed the transaction. The shares are subject to one year lock-up.
お知らせ • Jul 28INNOGENE Co.,Ltd. announced that it has received KRW 3.36 billion in funding from Metamorphosis Co., Ltd and Jeong Gi-chul.On July 27, 2026, INNOGENE Co.,Ltd. has closed the transaction.
New Risk • Jun 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩15.2b (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 43% per year over the past 5 years. High level of non-cash earnings (23% accrual ratio). Market cap is less than US$10m (₩15.2b market cap, or US$9.74m). Minor Risk Profit margins are more than 30% lower than last year (1.6% net profit margin).
New Risk • May 27New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 43% per year over the past 5 years. High level of non-cash earnings (23% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (1.6% net profit margin). Market cap is less than US$100m (₩18.0b market cap, or US$11.9m).
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₩1,334, the stock trades at a trailing P/E ratio of 69.9x. Average trailing P/E is 20x in the Personal Products industry in South Korea. Total loss to shareholders of 70% over the past three years.
お知らせ • Feb 06INNOGENE Co.,Ltd., Annual General Meeting, Mar 26, 2026INNOGENE Co.,Ltd., Annual General Meeting, Mar 26, 2026, at 10:00 Tokyo Standard Time. Location: conference room, guro-gu, seoul South Korea
Upcoming Dividend • Dec 22Upcoming dividend of ₩80.00 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 13 April 2026. Trailing yield: 3.8%. Within top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (1.8%).
New Risk • Dec 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 36% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Profit margins are more than 30% lower than last year (2.9% net profit margin). Market cap is less than US$100m (₩27.1b market cap, or US$18.3m).
お知らせ • Nov 12INNOGENE Co.,Ltd. announces Annual dividend, payable on April 13, 2026INNOGENE Co.,Ltd. announced Annual dividend of KRW 80.0000 per share payable on April 13, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
New Risk • Aug 28New major risk - Revenue and earnings growthEarnings have declined by 31% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (3.5% net profit margin). Market cap is less than US$100m (₩21.5b market cap, or US$15.5m).
New Risk • May 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩31.1b market cap, or US$22.3m).
New Risk • Jul 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (₩30.3b market cap, or US$22.0m).
New Risk • Aug 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (₩48.2b market cap, or US$36.0m).
お知らせ • Sep 07INNOGENE Co.,Ltd. has filed an IPO.INNOGENE Co.,Ltd. has filed an IPO. Security Name: Shares Security Type: Common Stock Price\Range: KRW 2500 to KRW 3000
Is New 90 Day High Low • Feb 24New 90-day high: ₩1,200The company is up 19% from its price of ₩1,010 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 13% over the same period.
お知らせ • Feb 10INNOGENE Co.,Ltd., Annual General Meeting, Mar 24, 2021INNOGENE Co.,Ltd., Annual General Meeting, Mar 24, 2021, at 10:00 Korea Standard Time.
Is New 90 Day High Low • Jan 05New 90-day high: ₩1,175The company is up 7.0% from its price of ₩1,100 on 07 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 9.0% over the same period.
